PDX, organoid or tumor fragment: choose by the question

Ask about this lesson

In one sentence

Choose a living model by the cells, surroundings and measurements your question needs, then check that those features still work in the actual preparation.

The intuition

You can study a plant by moving it into another garden, growing selected seeds in a greenhouse, or lifting a small patch of soil with its neighbors. Each makes a different experiment possible. None transports the entire original ecosystem.

A patient-derived xenograft (PDX) grows human tumor material in another species, commonly a mouse. An organoid is a three-dimensional culture that organizes into selected tissue features. An ex vivo tumor fragment is a piece or slice of living tissue studied outside its original body. These describe preparations. “Expose it to a reagent and track T-cell movement” describes an experiment. The preparation's name does not supply its controls, result or clinical usefulness.

How the three compare

The table describes common starting designs. Specialized immune-containing organoids, co-cultures and humanized grafts change the contents and require their own checks. They do not erase the distinctions. [1,2]

Check	Conventional PDX	Tumor organoid	Ex vivo tumor fragment
What researchers do	Implant human tumor material and establish growth in an animal	Establish and often expand a selected three-dimensional culture	Cut living tissue into pieces or slices for a defined experimental window
What may be retained	Useful human malignant-cell features and some tissue organization	Selected tumor populations and organization under culture conditions	Some original tumor cells, neighbors and local matrix architecture
What can change or be missing	Human supporting cells can be replaced by mouse stroma and vessels; conventional hosts lack an intact human immune system	Culture and passage select populations; conventional epithelial preparations may lack original immune and supporting cells	Cutting injury, diffusion and changing survival alter the preparation; visible vessels do not establish blood flow
Species and surroundings	Human tumor within a mouse; assign species to each relevant compartment	Tumor cells may be human; added cells, gel and medium have their own sources	Retained cells may be from the human sample; medium replaces bodily supply, and only a small region is sampled
Current function to demonstrate	Growth, exposure and the species-specific target interaction needed by this experiment	Relevant cell behavior and response now, rather than identity alone	Viability and the required local behavior now; an immune-cell stain alone does not prove a functional interaction
Selection and failures to retain	Submitted specimens, grafts established, passages and interpretable experiments	Submitted specimens, cultures established, normal-cell overgrowth, lost populations and usable assays	Collected samples, adequate tumor content, viable preparations and interpretable assays
A bounded question it can help answer	How does this characterized graft grow under measured mouse exposure?	How do these identified cultured tumor cells respond under controlled conditions?	How do retained local cells behave in this characterized tissue during the stated window?

Neither culture reproduces whole-body absorption, metabolism, healthy-organ toxicity or recruitment of new immune cells from the circulation. A mouse supplies circulation and whole-animal exposure, but its physiology is mouse physiology. A model response is therefore narrower than a human treatment-benefit claim. [1,3]

Three stacked fictional preparations. PDX P has human tumor cells within mouse supporting tissue and circulation. Organoid O contains selected human tumor cells in a supplied gel with no demonstrated T-cell compartment. Fragment F retains local human tumor cells, T cells and matrix in a cut tissue piece without perfused blood flow. These contents indicate what to check, not a hierarchy or a functional result.

These are the three fictional preparations below, not every PDX, organoid or fragment. Shapes identify example compartments, not cell fractions. Retention makes a question possible; direct measurements establish whether the needed behavior persists.

Work through a question before choosing

Welcome to MODEL-COMPARE-19. All preparations, exposures, observations and numbers below are invented for learning. They are separate from any patient or service offer.

The team asks: Does reagent M change the movement of resident human T cells toward identified malignant epithelial nests through the sample's retained local matrix during six hours? This asks about local movement and access, not tumor killing, immune recognition or patient benefit.

Three preparations are available:

Preparation	Characterized contents now	Function and history	Fit for this exact question
P: conventional PDX	Verified human tumor cells in an immunodeficient mouse; species checks identify mouse supporting cells and vessels; the required resident human T-cell population has not been demonstrated	Established graft, passage 2; growth and mouse circulation are observed	Mouse growth cannot substitute for the missing human T-cell/matrix context of the original sample
O: tumor-only organoid	Verified human malignant epithelial cells in a supplied gel; no T cells detected in the stated composition assay	Passage 3; viable growth under the specified medium, with culture selection recorded	Useful for a separate direct tumor-cell question; it lacks demonstrated T-cell movement through retained original tissue architecture
F: fresh tumor fragment	Characterized in the card below	No expansion or animal engraftment; required behavior checked over the proposed window	The candidate that contains this question's local components; it still needs the proposed controlled experiment

F's characterized fragment card

Field	Fictional record
Input and history	One human lung-tumor specimen, cut into matched adjacent slices; no culture expansion or graft passage. Pieces sample only part of the specimen
Tumor identity	Source-matched pathology and epithelial labeling identify malignant nests; the label alone is not the malignancy test
Retained compartments	Imaging identifies resident human T cells, stromal cells and collagen-rich local matrix beside malignant nests; spatial continuity is partly retained
Current function	Validated live labeling permits T-cell tracking. Matched run-in slices retain viable malignant cells and trackable T-cell movement throughout the six-hour handling window. This demonstrates the stipulated movement, not antigen-specific recognition or killing
Missing function and surroundings	Vessels may be visible, but no perfused circulation is demonstrated. There is no replenishment of blood-derived cells, human organ metabolism or whole-body toxicity test
Exposure and clock	Proposed M exposure: 0.5 micromoles per liter for six hours; matched carrier, medium and handling. This invented culture condition is not a human dose or an established assay protocol
Measurement	Prespecified T-cell track speed in micrometers per minute; fraction of initially eligible tracked T cells entering identified malignant nests during six hours. Fix eligibility, region boundaries and tracking rules before comparison
Controls and quality	Matched vehicle slices, baseline and end-window viability, label-only/phototoxicity checks and a prespecified motility-assay response control. Keep individual slice results and independent donor identities
Failure record	Poor viability, untrackable cells or absent malignant nests make the corresponding endpoint uninterpretable; exclusions keep their reasons and original denominators

Primary human lung-slice experiments show that movement and matrix relationships can be measured in a specified preparation. Their methods included introduced T cells as well as observations of resident cells; they do not validate this fictional resident-cell labeling or six-hour experiment. [4]

Answer the question-fit practice

1. Choose P, O or F for the team's exact movement question. Explain the choice and one remaining limit.

Answer: F is the candidate because its card demonstrates the required resident human T cells, local matrix and observable movement in the stated window. Compare M with vehicle using the specified tracking endpoints and quality checks. P and O, as currently characterized, do not contain the required context. F cannot establish new T-cell recruitment from blood, antigen-specific killing or clinical benefit. No M-versus-vehicle result has yet been supplied.

2. The team now asks whether M reduces the number of living malignant cells directly after 48 hours, without an immune mechanism. Must F still win?

Answer: No. O may support that narrower experiment if its 48-hour quality, exposures and attributed counts are checked. Compare starting and later counts with vehicle, and measure division and death separately when those claims matter. F's demonstrated six-hour window does not establish a viable 48-hour window. A whole-fragment metabolic decrease would also mix cell contributions. Changing the question changes the fit.

3. A third team asks about graft growth over a stated dosing schedule in a living mouse. Which preparation supplies that setting?

Answer: P supplies the living mouse setting. The team must specify measured mouse exposure, schedule, baseline burden, assessment time, animal controls and species-specific target binding. Its answer concerns that graft in that mouse context. Several mice from one donor are not several independent human donors; mouse dosing does not establish a safe or useful human treatment.

The three questions have three different possible fits. Adding immune cells to O or human components to P creates a revised preparation, whose compatibility and function must be characterized again.

4. Could the team choose F to show that a checkpoint-blocking antibody restores tumor-specific T-cell killing, because F contains moving T cells?

Answer: That conclusion remains untested in all three current records. F demonstrates movement, not tumor-specific recognition or killing. A suitable preparation would need persistent compatible cells, evidence for the required recognition interaction, attributed tumor-cell death and immune-function measurements, with appropriate antibody, tumor-only and recognition controls. Specialized immune organoids or supplemented grafts are possible revised designs, not capabilities supplied automatically by their names. Even a supported laboratory interaction leaves clinical usefulness unanswered.

Complete the experiment board

Model choice starts the plan. Carry the required fields into each proposed experiment rather than treating its name as a completed test. These records are fictional; an explicitly missing field remains a reason to pause.

Preparation	Required current components	Exposure and clock	Readout and controls	Remaining limit or missing evidence
P: does the characterized graft grow differently under regimen R in a mouse?	Growing human malignant cells; identified mouse host/support; verify any species-specific target interaction	Proposed regimen R over days 0–7; dose, route and measured mouse/tumor exposure are not supplied	Baseline and day-7 graft volume in cubic millimeters; matched vehicle animals and handling, baseline burden and exposure checks; retain donor, graft and animal counts	This plan is incomplete until regimen and exposure records are supplied. Growth below a later control is not necessarily regression below baseline, or a human treatment prediction
O: does M change viable malignant-cell counts directly over 48 hours?	Identified cultured malignant cells; no immune mechanism presumed; verify viability over the longer window	Proposed fictional 0.5 micromoles per liter M for 48 hours; matched medium/carrier and handling	Attributed viable tumor-cell count at start and 48 hours; vehicle, assay-response and mechanism controls; retain individual wells and donor identities	The current growth observation does not certify the whole 48-hour experiment. Measure division and death separately; medium exposure, culture selection and missing body systems limit the claim
F: does M alter local T-cell movement toward malignant nests over six hours?	Characterized resident T cells, malignant nests, some native matrix and demonstrated trackable movement	Proposed fictional 0.5 micromoles per liter M for six hours; matched carrier/handling	Track speed and predefined entry fraction; vehicle, label/phototoxicity, motility-response and viability controls from F's card	No M result yet; no perfused recruitment, tumor-specific killing or patient benefit supplied

Check the missing evidence: Which plan needs an exposure record before even interpreting its proposed dosing comparison?

Answer: P. “A PDX experiment” does not fill in regimen R. O and F have defined fictional culture exposures, but their quality and control results must also be documented before attributing an M effect. Extra wells, slices or animals improve measurement within a donor model; they do not turn one donor into several independent donors.

Keep models that failed in the denominator

Here are separate fictional cohorts. The model-response criteria belong to their different locked experiments, so their fractions cannot rank the three model families.

Model experiment	Specimens submitted	Preparations meeting its quality rule	Interpretable donor-model experiments	Meeting its model-response criterion
P: mouse graft-growth experiment	12	5 established grafts	4	2
O: direct tumor-cell count experiment	12	9 established cultures	8	4
F: local movement experiment	12	10 qualified fragments	9	3

Practice: What does F's 3/9 mean, and where do the other specimens go?

Answer: Three of nine interpretable donor-model experiments meet F's predefined movement criterion. Quality coverage is separately 10/12; interpretable-result coverage is 9/12. Two failed qualification and one additional qualified preparation failed to yield the endpoint. Retain all three with reasons. None is automatically a negative biological response or a resistant cancer. P's 2/4 and O's 4/8 describe different experiments and endpoints; they are not competing accuracy or clinical-response rates.

A primary breast-slice study likewise reported assay failures separately from evaluable results and limited its outcome comparison to a specified assay, treatment and imaging endpoint. That supports keeping failure and validation context visible; it does not establish universal fragment performance. [3]

Common confusions

“Patient-derived means patient-identical.” Sampling, culture and engraftment can select populations; current species and composition still matter.
“I can see T cells, so the immune mechanism works.” Presence, movement, target recognition and killing are different measurements.
“The more complex model is always better.” Complexity helps only when it supplies biology needed by the question.
“A successful assay makes a useful treatment decision.” Reproducibility and association with clinical outcomes are separate from evidence that using the result improves decisions and patient outcomes.

Explain it back

“Our question is ___. This preparation currently retains ___ and demonstrates ___. It omits ___. Our measured result could support ___.”

One answer: “a six-hour local movement response; resident T cells and some original matrix; trackable movement; circulation; an effect under these experimental conditions.”

Sources and scope

Author source reading: October 12, 2026. All MODEL-COMPARE-19 records are fictional. This teaches question fit, not a model procurement, tissue-collection or treatment recommendation. Independent scientific and learner review remain pending.

References

DeRose et al., 2011: primary breast-tumor graft study — selected establishment and species/stromal results personally read. The studied grafts retained useful tumor features while human stromal components changed; no universal PDX success rate is inferred.
Neal et al., 2018: tumor immune-microenvironment organoids — complete primary abstract read; full-text XML and rendered PMC access failed. It describes a specialized immune-containing method, not every organoid or this fictional preparation.
Ladan et al., 2023: specified breast-tumor slice assay — selected full-text Methods, Results and Discussion read, including quality rules, failures, diffusion and systemic/immune limitations. Original figure pixels, supplements and the full article were not reviewed.
Salmon et al., 2012: T-cell movement and matrix in human lung slices — selected primary Results, preparation/imaging passages and captions read. No original figure/video pixel or complete-method review is claimed; added-cell experiments are distinct from the fictional resident-cell tracking design.